Nanotherapeutics for enhancing thermal therapy of cancer

References

• Song CW, Park HJ, Lee CK, Griffin R. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 2005; 21(8)761–767
   PubMed Web of Science ®Google Scholar
• Huilgol NG. A phase I study to study arsenic trioxide with radiation and hyperthermia in advanced head and neck cancer. Int J Hyperthermia 2006; 22(5)391–397
   PubMed Web of Science ®Google Scholar
• Morita M, Kuwano H, Matsuda H, Mori M, Sugimachi K. Increased hyperthermic response with prostaglandin E1 in VX2 liver carcinoma in rabbits. J Natl Cancer Inst 1991; 83(19)1395–1400
   PubMedGoogle Scholar
• Shenoy MA, Singh BB. Studies on indomethacin as a potentiator for hyperthermic and radiation responses in a mouse fibrosarcoma. Cancer Lett 1989; 45(3)227–232
   PubMed Web of Science ®Google Scholar
• Song CW, Lin JC, Lyons JC. Antitumor effect of interleukin 1 alpha in combination with hyperthermia. Cancer Res 1993; 53(2)324–328
   PubMed Web of Science ®Google Scholar
• Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 1988; 48(3)650–653
   PubMed Web of Science ®Google Scholar
• Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: A vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001; 51(4)1018–1024
   PubMed Web of Science ®Google Scholar
• Murata R, Horsman MR. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2004; 20(4)393–404
   PubMed Web of Science ®Google Scholar
• Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncol 2001; 40(4)497–503
   PubMed Web of Science ®Google Scholar
• Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10(2)415–427
   PubMed Web of Science ®Google Scholar
• Dong D, Ko B, Baumeister P, Swenson S, Costa F, Markland F, Stiles C, Patterson JB, Bates SE, Lee AS. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res 2005; 65(13)5785–5791
   PubMed Web of Science ®Google Scholar
• Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, Maeda M, Urushizaki I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48(8)2179–2183
   PubMed Web of Science ®Google Scholar
• Waterston A, Bower M. TNF and cancer: Good or bad?. Cancer Therapy 2004; 2: 131–148
   Google Scholar
• Alikhani M, Alikhani Z, Raptis M, Graves DT. TNF-alpha in vivo stimulates apoptosis in fibroblasts through caspase-8 activation and modulates the expression of pro-apoptotic genes. J Cell Physiol 2004; 201(3)341–348
   PubMed Web of Science ®Google Scholar
• Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 1988; 167(3)1067–1085
   PubMed Web of Science ®Google Scholar
• van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11(4)397–408
   PubMed Web of Science ®Google Scholar
• Han B, Iftekhar A, Bischof JC. Improved cryosurgery by use of thermophysical and inflammatory adjuvants. Technol Cancer Res Treat 2004; 3(2)103–111
   PubMed Web of Science ®Google Scholar
• Lin JC, Park HJ, Song CW. Combined treatment of IL-1 alpha and TNF-alpha potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996; 12(3)335–344
   PubMed Web of Science ®Google Scholar
• Maeda M, Watanabe N, Yamauchi N, Tsuji Y, Niitsu Y. Successful treatment of a case of hepatocellular carcinoma with tumor necrosis factor and local hyperthermia. Gastroenterol Jpn 1991; 26(6)774–778
   PubMedGoogle Scholar
• Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 2005; 16(1)35–53
   PubMed Web of Science ®Google Scholar
• Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4(7)429–437
   PubMed Web of Science ®Google Scholar
• http://clinicalstudies.info.nih.gov/cgi/detail.cgi, ?A_2006-C-0167.html
   Google Scholar
• Paciotti GF, Myer L, Weinreich D, Goia D, Pavel N, McLaughlin RE, Tamarkin L. Colloidal gold: A novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004; 11(3)169–183
   PubMed Web of Science ®Google Scholar
• Visaria RK, Griffin RJ, Williams BW, Ebbini ES, Paciotti GF, Song CW. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery. Mol Cancer Ther 2006; 5(4)1014–1020
   PubMed Web of Science ®Google Scholar
• Chao BH, He X, Bischof JC. Pre-treatment inflammation induced by TNF-alpha augments cryosurgical injury on human prostate cancer. Cryobiology 2004; 49(1)10–27
   PubMed Web of Science ®Google Scholar
• Goel R, Swanlund D, Coad J, Paciotti GF, Bischof JC. TNF-α based Accentuation in Cryoinjury–Dose, Delivery and Response. Molecular Cancer Therapeutics 2007; 6(7)2039–2047
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Okajima K, Ogawa A, Song CW. Radiosensitization of two murine tumours with mild temperature hyperthermia and carbogen breathing. Int J Radiat Biol 1999; 75(10)1299–1306
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002; 62(6)1702–1706
   PubMed Web of Science ®Google Scholar
• Davison PM, Bensch K, Karasek MA. Isolation and growth of endothelial cells from the microvessels of the newborn human foreskin in cell culture. J Invest Dermatol 1980; 75(4)316–321
   PubMed Web of Science ®Google Scholar
• Basilico R, Blomley MJ, Cosgrove DO, Liull JB, Broillet A, Bauer A, Bonomo L. The first phase I study of a novel ultrasound contrast agent (BR14): Assessment of safety and efficacy in liver and kidneys. Acad Radiol 2002; 9(Suppl 2)S380–S381
   PubMed Web of Science ®Google Scholar
• Selby P, Hobbs S, Viner C, Jackson E, Jones A, Newell D, Calvert AH, McElwain T, Fearon K, Humphreys J, et al. Tumour necrosis factor in man: Clinical and biological observations. Br J Cancer 1987; 56(6)803–808
   PubMed Web of Science ®Google Scholar
• Feyerabend T, Steeves R, Wiedemann GJ, Richter E, Robins HI. Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Anticancer Res 1997; 17(4B)2895–2897
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Vujaskovic Z, Jones E, Thrall D. Re-setting the biologic rationale for thermal therapy. Int J Hyperthermia 2005; 21(8)779–790
   PubMed Web of Science ®Google Scholar
• Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 2006; 66(24)11520–11539
   PubMed Web of Science ®Google Scholar
• Thompson JF, de Wilt JH. Isolated limb perfusion in the management of patients with recurrent limb melanoma: An important but limited role. Ann Surg Oncol 2001; 8(7)564–565
   PubMed Web of Science ®Google Scholar
• van der Veen AH, Eggermont AM, Seynhaeve AL, van T, ten Hagen TL. Biodistribution and tumor localization of stealth liposomal tumor necrosis factor-alpha in soft tissue sarcoma bearing rats. Int J Cancer 1998; 77(6)901–906
   PubMed Web of Science ®Google Scholar
• Li CY, Dewhirst MW. Hyperthermia-regulated immunogene therapy. Int J Hyperthermia 2002; 18(6)586–596
   PubMed Web of Science ®Google Scholar
• Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol 2004; 22(4)592–601
   PubMed Web of Science ®Google Scholar
• Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res 2003; 20(9)1337–1350
   PubMed Web of Science ®Google Scholar
• Urano M, Kahn J, Kenton LA. The effect of cis-diamminedichloroplatinum(II) treatment at elevated temperatures on murine fibrosarcoma, FSa-II. Int J Hyperthermia 1990; 6(3)563–570
   PubMed Web of Science ®Google Scholar
• Roemer RB. Engineering aspects of hyperthermia therapy. Annu Rev Biomed Eng 1999; 1: 347–376
   PubMed Web of Science ®Google Scholar
• Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12(1)3–20
   PubMed Web of Science ®Google Scholar
• Farma JM, Puhlmann M, Soriano PA, Cox D, Paciotti GF, Tamarkin L, Alexander HR. Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer 2007; 120(11)2474–2480
   PubMed Web of Science ®Google Scholar
• Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006; 42(6)745–750
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cytokine Growth Factor Rev 2002; 13(2)135–141
   PubMed Web of Science ®Google Scholar